Antibacterial drug discovery: is it all downhill from here?
Open Access
- 1 January 2004
- journal article
- review article
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 10 (s4) , 18-22
- https://doi.org/10.1111/j.1465-0691.2004.1006.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for TherapyAntimicrobial Agents and Chemotherapy, 2003
- Do we really need new anti-infective drugs?Current Opinion in Pharmacology, 2003
- Discovery of a Novel and Potent Class of FabI-Directed Antibacterial AgentsAntimicrobial Agents and Chemotherapy, 2002
- N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial ActivityAntimicrobial Agents and Chemotherapy, 2002
- Trends in Fluoroquinolone (Ciprofloxacin) Resistance inEnterobacteriaceaefrom Bacteremias, England and Wales, 1990–1999Emerging Infectious Diseases, 2002
- Neonatal Bacteremia: Patterns of Antibiotic ResistanceInfection Control & Hospital Epidemiology, 2001
- Putting a price on biotechnologyNature Biotechnology, 2001
- New drug development in the United States from 1963 to 1999Clinical Pharmacology & Therapeutics, 2001
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001
- Multiple antibiotic resistance in Streptococcus pneumoniaeBritish Medical Bulletin, 1998